Journal of Internal Medicine 2004: Vol 256 Index

2004·1.3 MB·English

AUTHOR INDEX
Ferrannini, E. see Solini, A. Hultcrantz, R2. see Ormarsdottir, S.
Fioretto, P. see Solini, A. Hultdin, J., Thogersen, A.M., Jansson, J.-H., Nilsson, T.K.,
Fontana, D. see Coppola, A. Weinehall, L. & Hallmans, G. Elevated plasma homocysteine:
Forli, L., Halse. J., Haug, E., Bjortuft, 0., Vatn, M., Kofstad, J. & cause or consequence of myocardial infarction?, 491
30e, J. Vitamin D deficiency, bone mineral density and weight Hulthe, J. see Wallenfeldt. K.
in patients with advanced pulmonary disease, 56 Hurme, M. see Maury, C.P.J.
Fratiglioni, L. see Winblad, B. Hurt-Camejo, E. see Leinonen, E.S
Fujii, H. see Sato, T.
Fukuchi, Y. see Sato, T. Imbert, B. see Labarere, J.
Irjala, K. see Waseén, E.
Gansevoort, R.T. see Verhave, J.C. Isoaho, R. see Wasén, E.
Gansevoort, R.T. see Wulffelé, M.G.
Gareeboo, H. see Séderberg, S.
Jack, C. see Winblad, B.
Georgiades, A. see Janszky, | Jackson, S.L., Peterson, G.M.. Vial, J.H. & Jupe, D.M.L. Improving
Giacobini, E. see Winblad, B.
the outcomes of anticoagulation: an evaluation of home
Giannini, E.G. & Testa, R. Reply to Farina ti et al.: classification of follow-up of warfarin initiation, 137
‘intermediate stage’, untreated hepatocellular carcinoma
Jansen, A.C.M., Aalst-Cohen, E.S., Tanck, M.W.., Trip, M.D.
patients: the neighbour's grass is not so green, 531
Lansberg, P .J., Liem, A.H., Roeters van Lennep, H.W.O..,
Giugliano, D. see Coppola, A
Sijbrands, E.J.G. & Kastelein, J.J.P. The contribution of
Glatthor, C. see Hausleiter, J. classical risk factors to cardiovascular disease in familial
Gotzsche, P.C. see Hrobjartsson, A. hypercholesterolaemia: data in 2400 patients, 482
Graff, C. see Winblad, B.
Janssen, W.M.T. see Verhave. J.C
Graff-Iversen, S., Hammar, N., Thelle, D.S. & Tonstad, S$. Hormone Jansson, J.-H. see Hultdin, J.
therapy and mortality during a 14-year follow-up of 14 32
Janszky, I., Ericson, M., Lekander, M.. Blom, M.. Buhlin, K..
Norwegian women, 43> 7 Georgiades, A. & Ahnve, S. Inflammatory markers and heart
Grubb, A.O. see Christensson, A.G. rate variability in women with coronary heart disease, 421
Janzon, E., Hedblad, B., Berglund, G. & Engstrém, G. Tobacco and
Hallmans, G. see Hultdin, J. myocardial infarction in middle-aged women: a study of
Halse, J. see Forli, L. factors modifying the risk, 111
Hammar, N. see Graff-Iversen, S. Jarnerot, G. see Midhagen, G.
Hamsten, A. see Bartnik, M. Jelic. V. see Winblad, B.
Hansson, T. see Midhagen, G. Johansson, L. see Séderberg, S.
Hardy, J. see Winblad., B. Johansson, P., Kutti, J.. Andréasson, B.. Safai-Kutti. S.. Vilén. |
Hargrove, F. see Hulgan, T. Wedel, H. & Ridell. B. Trends in the incidence of chronic
Haug, E. see Forli, L. Philadelphia chromosome negative (Ph-) myeloproliferative
Hausleiter, J.. Kastrati, A., Mehilli, J.. Schithlen, H., Pache, J.. disorders in the city of Géteborg, Sweden, during 198 3-99,
Dotzer, F., Glatthor, C., Siebert, S., Dirschinger, J., Schomig. 16]
A. A randomized trial comparing phosphorylcholine-coated Jones. S. see Backman. L.
stenting with balloon angioplasty as well as abciximab with de Jong, P.E. see Verhave, J.C.
placebo for restenosis reduction in small coronary arteries, Jorm, A. see Winblad, B.
388 Juntikka. E.-L. see Luik, E.
Hedblad. B. see Janzon. E. Jupe, D.M.L. see Jackson, S.L.
Heikens, J.ebT:. see Stades, A.M.E.
Heine, R.J. see Spijkerman, A.M.W. Kaarela, K. see Maury, C.P.].
Held, P. see Wilhelmsen, L. Kastelein, J.J.P. see Jansen, A.C.M.
Henry, R.M.A. see Spijkerman, A.M.W. Kastrati, A. see Hausleiter, J.
Hillege, H.L. see Verhave, J.C. Kerkman, D. see de Leon, M.J.
Hino, O. see Sato, T. Kernodle, D.S. see Hulgan, T.
Hiukka, A. see Leinonen, E.S.
Kesadniemi, Y.A. see Santaniemi, M.
Hoekstra, J.B.L. see Stades, A.M.E. Keynan, Y. & Pottesman. I. Neurological symptoms in a traveller
Holleman, F. see Stades, A.M.E. returning from Central America, 174
Hollman. G., Ek, A.-C. & Olsson, A.G. Only one of four patients Kinra, S. & Davey Smith, G. Differential transmission of coronary
with familial hypercholesterolaemia reach cholesterol treat- disease risk to offspring is not supported by evidence, 260
ment goals in primary prevention, 176 Kivela, S.-L. see Wasén, E.
Holm, G. & Fagrell. B. Promotion of clinical science Key Kivipelto, M. see Winblad, B.
Symposium series in the honour of Axel Key, a pioneer in Kofstad, J. see Forli, L.
medicine, 179 Kooy. A. see Wulffelé, M.G.
Holmberg, E. see Luik, E. Kors, J.A. see Spijkerman, A.M.W.
Holmgren, G., Wikstrém, L., Lundgren, H.-E. & Suhr, O.B Kostense, P.J. see Spijkerman, A.M.W.
Discordant penetrance of the trait for familial amyloidotic Krakau, I. see Eriksson, M
polyneuropathy in two pairs of monozygotic twins, +53 Kumasaka, T. see Sato, T.
Hrobjartsson, A. & Gotzsche, P.C. Is the placebo powerless? Update Kupari, M., Turto, H. & Lommi, J. Diagnosing heart failure in
of a systematic review with 52 new randomized trials aortic valve stenosis. 381
comparing placebo with no treatment, 91 Kutti, J. see Johansson, P.
Hulgan, T., Rosenbloom, S.T., Hargrove, F., Talbert, D.A., Kutti, J. see Luik, E.
Arbogast, P.G., Bansal, P., Miller, R.A. & Kernodle, D.S. Oral
quinolones in hospitalized patients: an evaluation of a
computerized decision support intervention, 349
© 2004 Blackwell Publishing Ltd Journal of Internal Medicine 256:
AUTHOR INDEX
Labarere. J.. Bosson, J.-L., Br ].-P.. Fabre. M., Imbert, B.., Mehta, P.D. see de Leon, M.J.
Carpentier, P. & Pernod, G. Validation of a clinical guideline Mezzatzsta, G. see Mule, G.
on prevention of venous thromboembolism in medical Midhagen, G., Aberg, A.-K., Olcén, P., Jaérnerot. G., Valdimarsson,
inpatients: a before-and-after study with systematic ultra- [., Dahlbom, I., Hansson, T. & Strém, M. Antibody levels in
sound examination, 338 adult patients with coeliac disease during gluten-free diet: a
aiho see Maury, C.P.J rapid initial decrease of clinical importance, 519
Laine. M.. Luukkainen, R. & Toivanen, A. Sindbis viruses and Miller, R.A. see Hulgan, T.
other alphaviruses as cause of human arthritic disease, 45 Mongiovi. R. see Mule, G
air, L. see '| eon, M.] Mule, G., Cottone, S., Vadala, A.. Volpe, V.. Mezzatesta, G.
Lansberg see Jansen, A.C.M. Mongiovi, R., Piazza, G., Nardi, E., Andronico, G. & Cerasola,
Lappas, G. see Wilhelmsen, | G. Relationship between albumin excretion rate and aortic
Laukka., E.J. see Backman, I stiffness in untreated essential hypertensive patients, 22
Lavi, D. see Ofran, Y.
Leinonen, E.S., Hiukka. A.. Hurt-Camejo, E.. Wiklund, O., Sarna Nadar, S.K., Blann, A.D. & Lip, G.Y.H. Plasma and platelet-derived
S.S., Mattson Hultén, L.. Westerbacka, J.. Salonen. R.M. vascular endothelial growth factor and angiopoietin-1 in
Salonen, J.T. & Taskinen. M.-R. Low-grade inflammation, hypertension: effects of antihypertensive therapy. 331
endothelial activation and carotid intima-media thickness in Naessén, T. see Ormarsdottir, S.
type 2 diabetes, 119 Nannipieri, M. see Solini, A.
Lekander, M. see Janszky, | Nardi, E. see Mule, G.
de Leon, M.J.. DeSanti, S.. Zinkowski, R.. Mehta, P.D., Pratico, D.. Nasic, S. see Eliasson, M.
Segal, S., Clark, C.. Kerkman, D., DeBernardis, J.. Li, J.. Lair, Navis. G.J. see Verhave, J.C
L.. Reisberg, B.. Tsui. W. & Rusinek, H. MRI and CSF studies Niemela, K. see Vikman, S.
in the early diagnosis of Alzheimer’s disease, 205 Niemela, M. see Vikman, S.
Leosdottir, M., Nilsson, P., Nilsson, J.-A.. Mansson, H. & Berglund, Nieminen, M.S. see Vikman, S
G. The association between total energy intake and early Nijpels, G. see Spijkerman, A.M.W.
mortality: data from the Malm6 Diet and Cancer Study, 499 Nilsson, J. see Christensson, A.G
Li. J. see de Leon. M.]
Nilsson, J. . see Leosdottir, M
Liem, A.H. see Jansen, A.C.M Nilsson . see Nilsson, P.M
Liguori, E. see Coppola. A. Nilsson, P. see Fagerberg, B
Liljestr6m, M. see Maury, C.P.J Nilsson, P. see Leosdottir, M.
Lind, S., Olsson, A.G., Eriksson, M.. Rudling, M., Eggertsen, G Nilsson, P.M., Nilsson, J.-A. & Berglund, G. Reply to: Family
& Angelin, B. Autosomal recessive hypercholesterolaemia: history of CVD: the mother-son link revisited, 261
normalization of plasma LDL cholesterol by ezetimibe in
Nilsson, T.K. see Hultdin, J.
combination with statin treatment, 406 Nilsson, T.K. see Marklund, N.
Lip, G.Y.H. see Nadar, S.K.
Nordberg, A. see Winblad, B.
Lommi, J. see Kupari, M. Norhammar, A. see Bartnik, M.
LOOf, L. see Ormarsdottir, S. Norrgren, K. see Christensson, A.G.
Lowe, G.D.O. Hormone replacement therapy and cardiovascular
disease: increased risks of venous thromboembolism and
stroke, and no protection from coronary heart disease, 361 Ofran, Y., Lavi. D., Opher, D., Weiss, T.A. & Elinav, E. Fatal
Luik, E., Palk, K.. Everaus, H., Varik, M.. Aareleid. T.. Wennstrém, voluntary salt intake resulting in the highest ever docu-
L., Juntikka, E.-L., Safai-Kutti, S., Stockelberg, D., Holmberg, mented sodium plasma level in adults (255 mmol L™’): a
disorder linked to female gender and psychiatric disorders,
E. & Kutti, J. The incidence and survival of acute de novo
leukaemias in Estonia and in a well-defined region of western 525
Sweden during 1982-1996: a survey of patients aged > 65 Ohrvik, J. see Bartnik, M.
Olcén, P. see Midhagen. G.
years, 79
Lundgren, H.-E. see Holmgren, G. Oliviero, M. see Coppola, A.
Luukkainen. R. see Laine, M. Olsson, A.G. see Hollman, G.
Olsson, A.G. see Lind, S.
Olsson, T. see Marklund, N.
Majamaa-Voltti, K. see Vikman. S. Olsson, T. see S6derberg, S.
Mallmin, H. see Ormarsdottir, S$ Opher, D. see Ofran, Y.
Malmberg, K. see Bartnik. M Ormarsdottir, S., Mallmin. H., Naessén, T., Petrén-Mallmin, M.,
Mansson, H. see Leosdottir, M Broome, U., Hultcrantz, R. & LOOf, L. An open, randomized,
Mantovani, A. see Simon. A controlled study of transdermal hormone replacement
Marino, D. see Farinati, F. therapy on the rate of bone loss in primary biliary cirrhosis.
Marklund, N.,. Peltonen, M.. Nilsson, T.K. & Olsson, T. Low and
63
high circulating cortisol levels predict mortality and cognitive
dysfunction early after stroke, 15
Mattila, K. see Wasén, E. Pache, J. see Hausleiter, J.
Mattson Hultén, L. see Leinonen, E.S. Palk, K. see Luik. E.
Maury, C.P.J.. Liljestr6m, M., Laiho, K.. Tiitinen. S.. Kaarela, K. & Palmer, K. see Winblad, B.
Hurme, M. Anaemia of chronic disease in AA amyloidosis is Passaro, A. see Solini, A.
associated with allele 2 of the interleukin-1/-511 promoter Peltonen, M. see Marklund, N.
gene and raised levels of interleukin-1/ and interleukin-18, Perneger, T. see Bernard Bagattini, S.
145 Pernod, G. see Labarere, J.
van der Meer, J.W.M. see Bleijenberg, G. Perrier, A. see Bernard Bagattini. S.
van der Meer, J.W.M. see Simon, A. Petersen, R.C. see Winblad, B.
Mehilli, J. see Hausleiter, J. Petersen, R.C. Mild cognitive impairment as a diagnostic entity,
183
2004 Blackwell Publishing Ltd Journal of Internal Medicine 256: 532-536
AUTHOR INDEX
Peterson, G.M. see Jackson, S.L. Solini, A., Passaro, A., Fioretto, P., Nannipieri, M. & Ferrannini. E.
Petrén-Mallmin, M. see Ormarsdottir, S. Lipoprotein lipase gene variants and progression of nephro-
Petrozzi, L. see Vassalle, C. pathy in hypercholesterolaemic patients with type 2 diabetes,
Peuhkurinen, K. see Vikman, S. 30
Piazza, G. see Mule, G Spijkerman, A.M.W., Henry, R.M.A., Dekker, J.M.. Nijpels, G..
Pottesman, I. see Keynan, Y. Kostense, P.J., Kors, J.A.. Ruwaard, D., Stehouwer, C.D.A..
Pratico, D. see de Leon, M.J Bouter, L.M. & Heine, R.J. Prevalence of macrovascular
disease amongst type 2 diabetic patients detected by targeted
Reisberg. B. see de Leon, M.J. screening and patients newly diagnosed in general practice:
Ridell, B. see Johansson, P. the Hoorn Screening Study, 429
Ritchie, K. see Winblad, B. Stades, A.M.E., Heikens, J.T., Holleman, F. & Hoekstra, J.B.L.
Ritt, M. Reply to: metformin — current restrictions should be Metformin — current restrictions should be alleviated, 358
alleviated, 359 Stegmayr, B. see Sdderberg, S.
Rodu, B. see Eliasson, M. Stehouwer, C.D.A. see Spijkerman, A.M.W.
Roeters van Lennep, H.W.O. see Jansen, A.C.M. Stehouwer, C.D.A. see Wulffelé, M.G.
Rolandsson, O. What is the mechanism behind the association Stenlund, H. see Séderberg, S.
between autoantibodies against GAD65 and high body mass Sterner, G. see Christensson, A.G.
index?, 262 Stockelberg. D. see Luik, E.
Rosenbloom, S.T. see Hulgan, T. Stouten, B. Chronic fatigue syndrome: a clinical and laboratory
Rosengren, A. see Wilhelmsen, L. study with a well-matched control group, 265
Rudling, M. see Lind, S. Strdhle, A. & Wolters, M. Comment on the article ‘Genotype,
Rusinek, H. see de Leon, M.]J. obesity and cardiovascular disease — has technical and social
Ruwaard, D. see Spijkerman, A.M.W. advancement outstripped evolution?’, 86
Rydén, L. see Bartnik, M. Strom, M. see Midhagen, G.
Suhr, O.B. see Holmgren, G.
Sundkvist, G. see Christensson, A.G.
Safai-Kutti, S. see Johansson, P Sundkvist, G. see Schdlin. A.
Safai-Kutti, S. see Luik, E.
Svardsudd, K. see Bjérkegren, K
Salonen, J.T. see Leinonen, E.S. Svardsudd, K. see Eriksson, M.
Salonen, R.M. see Leinonen, E.S.
Santaniemi, M., Ukkola, O. & Kesaniemi, Y.A. Tyrosine phos-
phatase 1B and leptin receptor genes and their interaction in lalbert, D.A. see Hulgan, T.
type 2 diabetes, 48 Tanck, M.W. see Jansen, A.C.M.
Sarna, S.S. see Leinonen, E.S. askinen, M.-R. see Leinonen, E.S.
Sato, T., Seyama, K., Kumasaka, T., Fujii, H.. Setoguchi, Y., Tenerz, A. see Bartnik, M.
Shirai, T., Tomino, Y., Hino, O. & Fukuchi, Y. A patient with ‘esta, R. see Giannini, E.G
TSC1 germline mutation whose clinical phenotype was Thelle, D.S. see Graff-Iversen, S
limited to lymphangioleiomyomatosis, 166 ‘hogersen, A.M. see Hultdin, J.
Schélin, A. & Sundkvist, G. Reply to: what is the mechanism lierala, I. see Vikman, S
behind the association between autoantibodies against ‘jitinen, S. see Maury. C.P.]J.
GAD6S and high body mass index?, 264 Toivanen, A. see Laine, M.
Schémig, A. see Hausleiter, J. ‘omino, Y. see Sato, T.
Schiihlen, H. see Hausleiter, J. Tonstad, S. see Graff-Iversen. S.
Segal, S. see de Leon, M.J. ‘revisani, F. see Farinati, F.
Setoguchi, Y. see Sato, T. Trip, M.D. see Jansen, A.C.M.
Seyama, K. see Sato, T. Tsui, W. see de Leon, M.J.
Shaw, J. see S6derberg, S. ‘umber, M.B. & Dickersin, K. Publication of clinical trials:
Shirai, T. see Sato, T. accountability and accessibility 27711
Tuomilehto, J. see Séderberg, S
Siebert, S. see Hausleiter, J.
Sijbrands, E.J.G. see Jansen, A.C.M. rurto, H. see Kupari, M.
Silveira, A. see Bartnik, M. Tuunanen, H. see Vikman, S.
Simon, A., Bijzet, J., Voorbij, H.A.M., Mantovani, A., van der
Meer, J.W.M. & Drenth, J.P.H. Effect of inflammatory attacks Ukkola, O. see Santaniemi. M.
in the classical type hyper-IgD syndrome on immunoglobin
D, cholesterol and parameters of the acute phase response, Vadala, A. see Mule, G.
247 Vahlberg, T. see Wasén, E
S. see Wehren, L.E. Valdimarsson, T. see Midhagen, G.
Sjéstrom, L.-G. see Sdderberg, S. Varik, M. see Luik, E.
Small, B.J. see Backman, L. Vassalle, C., Petrozzi, L., Botto, N., Andreassi. M.G. & Zucchelli.
Séderberg, S., Stegmayr, B., Stenlund, H., Sjéstrém, L.-G., Agren, G.C. Oxidative stress and its association with coronary artery
A., Johansson, L., Weinehall, L. & Olsson, T. Leptin, but not disease and different atherogenic risk factors, 308
adiponectin, predicts stroke in males, 128 Vatn, M. see Forli, L.
Séderberg, S., Zimmet, P., Tuomilehto, J., de Courten, M., Dowse. Vercoulen, J.H.H.M. see Bleijenberg, G.
G.K., Chitson, P., Stenlund, H., Gareeboo, H.. Alberti, Verhave, J.C., Hillege. H.L.. Burgerhof, J.G.M., Janssen, W.M.T.,
K.G.M.M. & Shaw, J. High incidence of type 2 diabetes and Gansevoort, R.T., Navis, G.J., de Zeeuw, D., de Jong. P.E. for
increasing conversion rates from impaired fasting glucose the PREVEND study group. Sodium intake affects urinary
and impaired glucose tolerance to diabetes in Mauritius, 37 albumin excretion especially in overweight subjects, 324
Vial, J.H. see Jackson, S.L.
© 2004 Blackwell Publishing Ltd Journal of Internal Medicine 256: 532
AUTHOR INDEX
Vikman, S., Airaksine Tierala, I., Peuhkurinen, K.. Westerbacka, J. see Leinonen, E.S.
Majamaa-Voltti. K mela, M.. Tuunanen, H., Nieminen Wiklund, O. see Leinonen, E.S
M.S. & Niemela. K. ywroved adherence to practice guidelines Wikstrand, J. see Wallenfeldt, K
vields better out 1c in high-risk patients with acute Wikstrém, L. see Holmgren, G.
coronary syndrome withot leva findings from Wilhelmsen, L., Held, P. & Wedel, H. Clinical trials: a summary,
nationwide FINACS studies, 316 284
Johansson, P Wilhelmsen, L., Lappas, G. & Rosengren, A. Risk of coronary
Winblad. B events by baseline factors during 28 years follow-up and
fule. G three periods in a random population sample of men, 298
A.M. se ‘ Winblad, B., Palmer. K.. Kivipelto, M.. Jelic, V. & Fratiglioni, L.
Introduction: Mild cognitive impairment: beyond controver-
. towards a consensus, 181]
K., Kivipelto, M.. Jelic. V.. Fratiglioni, L.,
Nordberg. A., Backman, L., Albert, M..,
rai, H., Basun, H.. Blennow, K., De Leon, M..,
Erkinjuntti, T., Giacobini, E., Graff, C., Hardy, J..
Jorm, A.. Ritchie, K., van Duijn. C., Visser, P. &
..C. Mild cognitive impairment - beyond contro-
versies, towards a consensus: report of the International
shiaalie ak aie ri as ye atinine-based formulae with Working Group on Mild Cognitive Impairment, 240
: Wolters. M. see Strdhle, A
serum
Wulffelé, M.G., Kooy, A., de Zeeuw, D., Stehouwer, C.D.A. &
Gansevoort, R.T. The effect of metformin on blood pressure.
lasma cholesterol and triglycerides in type 2 diabetes
e mineral density: can Bi RAMOS ]
ruments identify women
5 a j
d}e Zeeuw
Zimmet
Zinkows
Zuccnehe lli
2004 Blackwell Publishing Ltd Journal of Internal Medicine 256: 532-536
Journal of Internal Medicine 2004; 256: 537
Keyword index
acute contiguous gene syndrome, idiopathic myelofibrosis, 161
coronary syndrome, 316 coronary immunoglobulin D, 247
de novo leukaemia, 79 artery disease, 308 >I SS impaired fasting glucose, 37
myocardial infarction, 288 circulation, 398 impaired glucose tolerance. 37, 288
phase response. 247 heart disease, 298, 361, implementation, 316
adiponectin, 128 cortisol, 15 incidence, 37, 79, 101, 161
adult height, 472 C-reactive protein, 421 inflammation, 119
ageing. 183 creatinine, 491, 510 INR monitoring. 137
albumin, 49] CVD. 119 interleukin-6, 421
alphaviruses, 457 cystatin C, 510 nterleukin-18, ] 145
\lzheimer’s disease, 18 interleukin-1
240 definition, 240 polymorphisms, 145
amyloidosis, 145, 453 dehydroepiandrosterone receptor antagonist, 42]
anaemia of chronic disease, diabetes, 119, 288, 472 /-511 gene polymorphism, 145
angiopoietin-1, 331 mellitus, 37, 101 mic stroke, 15, 128
antibiotics, 349 nephropathy. 30 isoprostane, 308
antibody response, 5
diagnosis, 153
anticoagulation, 137
antioxidant, 398 GI1c rt 519 Karelian fev
differential diagnosis
aortic d1i sorientation, 15
stiffness, 22 Doppler echo-cardiography
valve stenosis, 38] dysesthesia, 174
arterial hypertension,
dyslipidaemia
atheroma, 41 3
atherosclerosis, 308, 413
authorship, 271 ‘arly diagnosis, in lipase polymorphisms
autosomal recessive hyper- dfuecara)t ion, 137a e
cholesterolaemia, 406 ‘lectronic publishing. longitudinal.
endothelium, 119 long-term follow-up, 298
epidemiology, 101, 429, 437 lymphangioleiomyomatosis, 166
balloon angioplasty, 388
essential thrombocythaemia, 161
B-amyloid, 224
Estonia, 79
biliary. 63
zetimibe, 406
biomarkers, 2
birth weight, 2 Mauritius
blood pressure, familial hypercholesterolaemia. 406 MCI, 205,
body family history, 298 memory, |
composition ferritin, 247 meta-analysis, 1, 91
size, 254 filtration, 30 metab¢ syndrome
bone fish poisoning. metiormin
density. 63 folate. 446 methylmalonic acid, 446
mineral density, 56 forme fruste, 166 microalbuminuria, 2>2 . 20 , 524
mineral density testing, >3 75 mild cognitive impairment 183, 23 5
gene—gene interaction, 48 240
calcium channel blockers, 33 genetics, 453 Modification of Diet in Renal Disease
caloric intake, 499 genetics and dementia, 235 formula, 70
cancer, 499 germline mutation, 166 mortality, 15, 499
cardiovascular, 499 glomerular, 30 MRI, 205
filtration rate, 70 multivariate analysis, 153
driisske,a se2,2 429 37,472. 482 glycoprotein II[b/IIla antagonists, 388 myeloproliferative disorders. 161
risk factor, 32 guidelines, 316 myocardial infarction, 111. 491
cerebrospinal fluid, 224
chemokines, 398 haemorrhage, 1 37 natriuretic peptides, 381
cholesterol. 1, 111 haemorrhagic stroke, 128 1ephropathy. 510
Ciguatera, 174 heart nested case-referent study. 128
Ciguatoxin, 174 failure, 381 neuropathy, 453
clinical rate variability. 421
criteria. 240 heparin, 338 obesity. 324
decision support systems, high density lipoprotein, 254 occupation and marital status, 111
trials, 271 homocysteine, 398, 446, 491 Ockelbo disease, 457
coagulation, 361 hormone oestrogen, 63
Cockcroft-Gault formula, 70 replacement therapy. ¢ oral, 525
coeliac disease, 519 treatment, 437 osteoporos: is, 63,2 3
cognition, 15, 195 hypercholesterolaemia. oxidative stress, 308
cohort studies, 37, 101 hyper-IgD syndrome, 247
conflict of interest, 271 hypernatraemia, 525
pain, 91
consensus, 240 hypertension, 111, 23 31 paresthesia, 174
© 2004 Blackwell Publishing Ltd
KEYWORD INDEX
pentraxin-3, 247 risk transition, 195
placebo effect, 91 assessment, 375 transplantation, 56
placebos, 91 determinants, 491 treatment trial, 446
platelet, 331, 388 factors, 128, 298, triglycerides, 1, 254
Pogosta disease, 457 stratification, 316 tuberous sclerosis complex, 166
polycystic kidney disease, 166 type 2
polycythaemia vera, 161 screening, 375, 429 diabetes. 30, 48, 429
population, 499 serum diabetes mellitus, 1
preclinical, 195 creatinine, 70 tyrosine phosphatase 1B,2 48
dementia. 240
cystatin C, 70
prediction rule, 153 Sindbis viruses. 457 ultrasonography, 413
prevalence, 101, 288 single nucleotide polymorphism, 48 urinary sodium excretion, 324
prevention, 338
pP-rsoeclaelcctiitno,n in,3 247 ssmmookkeilnegs,s , 1111] 01 vascular endothelial growth factor, 331
psychiatric, sodium, 525 venous thrombosis, 338, 361
publication bias, 27 statin, 406 viral arthritis, 457
publishing, 271 stents, 388 vitamin
pulmonary stress, 298 B12, 446
disease. 56 ssturrovkiev,a l, 367] 9 D, 56
embolism, 153, 33 Sweden, 79
pulse wave velocity. symptoms, 446 warfarin, 137
systematic review, 1, 9] weight, 56
quinolones, 349 women, 111, 421
women’s health, 437
tau proteins, 224
renal function, 510 tobacco, 101
restenosis. 388 total antioxidant capacity, 308
2004 Blackwell Publishing Ltd Journal of Internal Medicine 256: 5